safety

Radicava ORS, an oral formulation of edaravone recently approved to treat amyotrophic lateral sclerosis (ALS) in the U.S., was safe and generally well-tolerated over almost a year of treatment in a Phase 3 clinical trial, new data highlight. The results were presented by the therapy’s developer, Mitsubishi Tanabe…

AB Science’s proposed measures to ensure patient safety in clinical trials of its experimental oral therapy masitinib were deemed sufficient by the French National Agency for Medicines and Health Products Safety (ANSM), and patient enrollment in the country may resume. The announcement comes less than two months after…

Among the many challenges of living with ALS are the physical symptoms of muscle stiffness and weakness. I have both. During my first year with ALS, I’d wake up and walk into the bathroom doing a good imitation of the clumsy, lurching steps of Frankenstein’s monster. On other days,…

I thought my husband, Todd, should quit driving long before he was ready to hang up the keys. When ALS had weakened his left arm and right hand, he would get gas from a full-service station. I questioned whether he should be driving when he couldn’t pump gas for himself.

In 2010, a few short months after my ALS diagnosis, I found myself having to rely full time on a rollator. I’ll be the first to admit I wasn’t happy at all. But now, nine years later, it’s become my ever-present silent buddy, and I can’t imagine my life…

I’ve always believed that I was open to new ways of doing things, but having ALS has put me to the test. My pride and a little denial have often gotten in the way of my seeing the obvious solutions to a problem. Thank goodness an “aha” moment came…

Anelixis Therapeutics has begun dosing patients in the first human trial of its amyotrophic lateral sclerosis (ALS) treatment candidate, AT-1501, the company announced. The trial is currently enrolling both healthy volunteers and eight ALS patients to test AT-1501’s safety and tolerability. Researchers will also examine how the agent behaves…

Treatment with a compound called inosine over 12 weeks increased the levels of the antioxidant urate, a neuroprotective agent, in patients with amyotrophic lateral sclerosis (ALS), according to a pilot trial. The investigational therapy also showed a positive safety and tolerability profile, indicating it might have potential as an…

Investigational compound EPI-589 was found to be safe and well-tolerated, improved biomarkers of neuroinflammation, and showed signs of slowing disease progression in amyotrophic lateral sclerosis (ALS) patients, according to a completed Phase 2a clinical trial. BioElectron Technology Corporation’s EPI-589, or (R)-troloxamide quinone, is a 250 mg immediate-release, film-coated…

MediciNova has completed enrollment for its Phase 1/2 clinical trial testing the investigational therapy MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) patients. The trial (NCT02714036) has enrolled 35 ALS patients who will be treated with 100 mg daily doses (50 mg twice a day) of MN-166. The…